Sugi Predict

Sugi Predict / Targets / GRM8

GRM8

Metabotropic glutamate receptor 8 · O00222 · GRM8 on Sugi Atlas →

22,396 patent compounds predicted against GRM8, 14,664 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL346142 SCHEMBL346142 1.00 19/20
SCHEMBL56509 SCHEMBL56509 0.57 19/20
SCHEMBL56829 SCHEMBL56829 0.53 19/20
SCHEMBL56510 SCHEMBL56510 0.60 17/20
SCHEMBL56830 SCHEMBL56830 0.56 15/20
SCHEMBL346141 SCHEMBL346141 0.66 14/20
SCHEMBL346140 SCHEMBL346140 0.55 14/20
SCHEMBL346473 SCHEMBL346473 0.51 10/20
SCHEMBL346474 SCHEMBL346474 0.51 10/20
SCHEMBL346779 SCHEMBL346779 0.54 9/20
SCHEMBL346780 SCHEMBL346780 0.54 9/20
SCHEMBL353510 SCHEMBL353510 0.52 8/20
Eglumetad Eglumetad (SCHEMBL231157) 1.00 7/20
SCHEMBL369315 SCHEMBL369315 0.61 5/20
SCHEMBL56156 SCHEMBL56156 0.53 5/20
SCHEMBL57236 SCHEMBL57236 0.62 4/20
SCHEMBL56157 SCHEMBL56157 0.55 4/20
SCHEMBL56061 SCHEMBL56061 0.49 4/20
SCHEMBL160783 SCHEMBL160783 0.54 3/20
SCHEMBL38175 SCHEMBL38175 0.53 3/20

Clinical trials — most relevant to GRM8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery. PHASE4COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Memantine for Refractory OCD Patients PHASE3UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) PHASE2/PHASE3RECRUITING
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation PHASE3COMPLETED
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
TRPM8 Activators for Peripheral Neuropathy PHASE2ACTIVE_NOT_RECRUITING
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder PHASE2WITHDRAWN
A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue PHASE1/PHASE2COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
Antidepressant Effects of NR2B in Major Depression PHASE1COMPLETED
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain PHASE1COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Acamprosate: Genes Associated With Response nanCOMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
Sleep/Wake Cycle and Depression: An Imaging and Treatment Study nanCOMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GRM8 binder may also engage these)

ProteinNameSimilarity
P47743 — 1.000 P47743 →
P70579 — 1.000 P70579 →
Q68ED2 — 1.000 Q68ED2 →
Q5RDQ8 — 1.000 Q5RDQ8 →
P35400 — 0.998 P35400 →
GRM7 Metabotropic glutamate receptor 7 0.995 landscape →
GRM4 Metabotropic glutamate receptor 4 0.971 landscape →
P31423 — 0.969 P31423 →
Q1ZZH0 — 0.967 Q1ZZH0 →
Q68EF4 — 0.965 Q68EF4 →
Q9ULV1 — 0.946 Q9ULV1 →
Q9IA05 — 0.944 Q9IA05 →
Q61088 — 0.944 Q61088 →
GRIN3A Glutamate receptor ionotropic, NMDA 3A 0.944 landscape →
Q9R1M7 — 0.939 Q9R1M7 →
A2AIR5 — 0.939 A2AIR5 →
Q9QZH0 — 0.937 Q9QZH0 →
Q7TMS5 — 0.937 Q7TMS5 →
TRPC7 Short transient receptor potential channel 7 0.937 landscape →
Q5MB13 — 0.935 Q5MB13 →
P70704 — 0.933 P70704 →
GRM6 Metabotropic glutamate receptor 6 0.933 landscape →
P98200 — 0.933 P98200 →
C7EXK4 — 0.931 C7EXK4 →
Q8MIB3 — 0.931 Q8MIB3 →
Q7Z2H8 — 0.931 Q7Z2H8 →
Q5NCH9 — 0.931 Q5NCH9 →
Q9WVC5 — 0.931 Q9WVC5 →
Q80W57 — 0.930 Q80W57 →
P35349 — 0.930 P35349 →